$NDAQ

SEC to review Nasdaq bitcoin options approval after CME challenge

The SEC paused Nasdaq PHLX’s conditional approval of cash-settled bitcoin index options under ticker QBTC, saying it will reconsider after CME Group challenged the decision. CME argues bitcoin options fall under CFTC jurisdiction because bitcoin is a commodity. The approval stays frozen while the SEC reviews, with comments due Aug. 24.

Original reporting
Published Aug 1, 2026, 6:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 1, 2026, 7:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefRegulation
Primary signal
$NDAQ
Neutral
medium confidence
Mentioned
$NDAQ
Relevance
8/10
alphai data visualization · based on coindesk.com
Decision brief

The 30-second read

$NDAQNeutralMed
01

Why it matters

CME challenged the approval in June, arguing bitcoin is a commodity and the SEC lacks authority; the SEC has now paused the product while it reconsiders and solicits comments through Aug. 24.

02

Market read

Traders in crypto-derivatives and exchange operators face a near-term catalyst: SEC reconsideration of QBTC approval after CME’s jurisdiction challenge.

03

What to watch

Outcome may hinge on whether the SEC views the index and settlement mechanics as security-linked versus commodity-linked, and on how exemptions are interpreted across agencies.

Relevance 8/10Novelty 8/10Timing: SEC order freezes QBTC approval now; comments due Aug. 24.

Background

In May, the SEC granted Nasdaq PHLX conditional approval to list cash-settled bitcoin index options under QBTC, pending CFTC exemptions.

Company-level read

Ticker impact

$NDAQNeutralMedium confidence
Context

SEC froze Nasdaq PHLX’s conditional approval for cash-settled bitcoin index options under ticker QBTC, pending review of CME’s challenge.

Expected impact

Volatility risk around regulatory headlines; direction depends on whether SEC ultimately sustains or reverses the approval.

Evidence & confidence

The article is a direct regulatory stay on a specific Nasdaq product approval, which can affect launch timing and competitive positioning versus CME.

Market effects

Sets a precedent risk for how US regulators classify crypto derivatives, potentially affecting other exchange product approvals and contract structuring.

US-focused impact on exchange-traded crypto derivatives; spillover to global venues offering similar products.

Could influence international regulatory approaches to crypto derivatives jurisdiction and settlement mechanics.

Counterpoint

Even with a stay, the SEC may ultimately uphold the approval if it finds sufficient basis for securities-market treatment via exemptions.

Key entities

  • Nasdaq PHLX

    Exchange seeking to list cash-settled bitcoin index options under QBTC, now subject to an SEC stay.

  • CME Group

    Filed the legal challenge arguing CFTC jurisdiction over bitcoin commodity-linked options.

  • SEC

    Paused and will reconsider Nasdaq’s QBTC options approval, with a comment deadline of Aug. 24.

Related articles

$NDAQMed

SEC sets Aug. 24 deadline in Nasdaq Bitcoin options review

The SEC ordered a full Commission review of Nasdaq PHLX’s proposed cash-settled Bitcoin index options (QBTC), after CME Group petitioned against a May 22 staff approval. The SEC set Aug. 24 as the deadline for written comments. The May approval remains stayed pending the Commission’s next order, with CFTC and OCC relief still required.

$CMEMed

CME Challenges Nasdaq Bitcoin Options Approval, Claims CFTC Has Exclusive Jurisdiction — BigGo Finance

CME Group challenged the SEC’s conditional approval of Nasdaq PHLX’s cash-settled bitcoin index options (ticker QBTC). CME says bitcoin is a commodity, so CFTC has exclusive jurisdiction, and the SEC exceeded its authority. The SEC initiated review and kept a stay. Comments are due Aug. 24. QBTC uses CME CF Bitcoin Real-Time Index and is cash-settled in USD.

$NDAQMedAI 8/10

Nasdaq (NDAQ) Q2 2026 Earnings Call Transcript

Nasdaq (NDAQ) reported Q2 2026 net revenue of $1.5 billion, up 15%, and non-GAAP EPS of $1.07, up 25%. Solutions revenue rose 17% to $1.2 billion, with Index AUM reaching $1.114 trillion and $51 billion in quarterly net inflows. The company updated non-GAAP operating expense guidance to $2.530 billion to $2.570 billion and repurchased $356 million of shares.

$NDAQMedAI 9/10

Nasdaq Q2 Earnings: Double-Digit Revenue Growth Across All Divisions

Nasdaq (NDAQ) reported Q2 results with quarterly net revenue of $1.5 billion, up 15% on an adjusted basis. Solutions revenue rose 17% adjusted. ARR increased 11% to $3.3 billion. GAAP diluted EPS was $0.89, up 14%, and non-GAAP EPS was $1.07. Nasdaq also cited record Index AUM and IPO activity, including SpaceX.

$NDAQMed

Nasdaq Q2 2026 earnings beat on SpaceX IPO, data revenue

Nasdaq reported Q2 2026 net revenue of $1.5 billion, up 15%, and adjusted EPS of $1.07 versus $0.98 expected, according to Reuters. Capital access platforms revenue rose 19% to $621 million, helped by listing activity including SpaceX’s IPO. Market services and fintech revenue also increased. Nasdaq declared a $0.31 quarterly dividend.